Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Oscillating Pulsed Electric Fields Strike Major Blow to Resistant Bacteria and Cancer

By BiotechDaily International staff writers
Posted on 29 Oct 2013
Image: Time lapse photos of three leukemia cells being treated with OPEF. Two of the three cells are literally shattered by the treatment (Photo courtesy of PRNewsFoto/Novobiotronics Inc.).
Image: Time lapse photos of three leukemia cells being treated with OPEF. Two of the three cells are literally shattered by the treatment (Photo courtesy of PRNewsFoto/Novobiotronics Inc.).
Oscillating pulsed electric field (OPEF) technology is delivering a one-two punch against cancer and antibiotic-resistant bacteria using a pulsed electronic signal that destroys cancer cells and disables antibiotic resistance in deadly methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas bacteria.

Novobiotronics (Saratoga Springs, NY, USA), a world leader in research on the biologic effects of OPEFs as a future nontoxic medical treatment, was the first company to confirm the capability of OPEFs to destroy 30%–60% of leukemia cells. In laboratory research, OPEF also demonstrated an ability to slow cancer growth by up to 60%. OPEF has also shown an ability to disarm antibiotic resistance in the lethal bacteria MRSA, rendering it susceptible to typically available antibiotics as well as inhibiting its growth.

Novobiotronics Inc., a nonprofit educational and scientific research, has report a significant breakthrough in the battle against cancer and harmful antibiotic-resistant strains of bacteria including the “superbug” deadliness of MRSA, and Pseudomonas aeruginosa (PS).

Anthony Holland, president of Novobiotronics, reported the findings of recent laboratory research done in collaboration with the State University of New York (Stony Brook, USA) that their new electronic treatment of antibiotic resistant MRSA and PS has both a bacteriostatic effect as well as a bactericidal effect when used in combination with tiny amounts of conventional antibiotics to which the deadly organisms are otherwise normally resistant.

The current standard medical treatment of antibiotic-resistant bacterial infections utilizes combinations of different types of antibiotics, but those combinations can result in very serious and even dangerous side effects. Physicians even induce some patients into a coma to reduce the severity of the drug side effects.

Novobiotronics’ new technology involves the use of a “plasma antenna,” a type of a helium gas filled fluorescent light used to broadcast oscillating pulsed electric fields at cancer cells and bacteria. These OPEFs can kill cancer cells, slow the growth rate of the cancer cells and bacteria greatly, and actually quash the bacteria’s ability to resist antibiotics. When used in combination with very small amounts of a traditional antibiotic, OPEF has demonstrated an ability to destroy MRSA and PS bacteria.

Novobiotronics’ collaborators from the State University of New York presented their joint findings at a September 2013 meeting of the American Society for Microbiology, held in Denver (CO, USA).

Related Links:

Novobiotronics
State University of New York



Channels

Genomics/Proteomics

view channel
Image: The photomicrograph shows the head of a mouse embryo in which the pericytes are visible as blue dots along the blood vessel (Photo courtesy of the University of Gothenburg).

Genetically Engineered Mouse Model Reveals Key to Formation of the Blood-Brain Barrier

Use of a mouse model that had been genetically engineered to lack the gene that encodes the forkhead transcription factor Foxf2 has helped to explain how pericytes, cells that line the capillaries, form... Read more

Drug Discovery

view channel
Image: Scanning electron microscope (SEM) image of a field of polypyrrole nanowires (Photo courtesy of Dr. Richard Borgens, Purdue University).

Novel Controlled-Release Drug Delivery System Heals Spinal Inflammation in Mouse Model

A novel drug delivery system that allows controllable release of an anti-inflammatory agent directly to the site of inflammation or injury was tested successfully in a mouse model. Investigators at... Read more

Business

view channel

Biopharm Startup to Commercialize Antibody Therapy for Drug Resistant Cancers

A biopharm startup company has licensed the rights to commercialize an antibody-based approach for treatment of drug resistant cancers. The new company, CadheRx Therapeutics (La Jolla, CA, USA), entered into a licensing agreement with Stony Brook University (NY, USA) to develop and market an anticancer technology derived... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.